BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Xencor’s Fc Engineered Antibody Suppresses Autoimmunity in Preclinical Systemic Lupus Erythematosus Models; Data Published in Journal of Immunology


3/9/2011 10:12:37 AM

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. announced positive results from preclinical studies of XmAb®5871, a humanized monoclonal antibody that dually targets CD19 and CD32b (Fc?RIIb) for the treatment of autoimmune diseases, demonstrating that XmAb5871 is a potent suppressor of B cell activation ex vivo and of autoimmune response in humanized mouse models. XmAb5871 consists of an Fc domain engineered by Xencor to produce a 400-fold greater affinity for binding to the CD32b receptor and for co-engaging with the BCR complex. Researchers concluded that XmAb5871 may be an effective immunosuppressant in multiple in vivo settings including systemic lupus erythematosus (SLE), and can globally suppress autoimmune response without B cell depletion. The results are published in the April 1, 2011 issue of The Journal of Immunology.

Read at BioSpace.com

Xencor
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->